#	Pagina
attuale pagina	/open-h2020/projects/219838/index.html
-1	/open-h2020/projects/197956/index.html
-2	/open-h2020/per-topic/facet/list/index.html
-3	/open-h2020/projects/212259/index.html
-4	/open-h2020/projects/219810/index.html
-5	/open-h2020/projects/222679/index.html
-6	/open-h2020/per-topic/combacte/list/index.html
-7	/open-h2020/projects/222726/index.html
-8	/open-h2020/projects/211818/index.html
-9	/open-h2020/per-topic/espss/list/index.html
-10	/open-h2020/per-topic/aave/list/index.html

Opendata, web and dolomites

UPGRADE SIGNED

Unlocking Precision Gene Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

UPGRADE project word cloud

Explore the words cloud of the UPGRADE project. It provides you a very rough idea of what is the project "UPGRADE" about.

sequence limitations remarkable diseases amp solutions efficiency market medicinal tissue indications heart incurable broaden strategies validated hematopoiesis amps wasting epigenome poor treatments hypercholesterolemia blood overcome disruptive insertional tissues radical gene models specificity evasion off transgene prototypes opening medical unmet upgrade mutagenesis cellular technologies tackling therapy groups pathogenesis liver combine treatment viral paradigmatic profile clinical conventional safety site editing tools stringently skeletal muscle complementing cell silence cure storage retina insertion precise realize activate versatile seven durability transfer correction genome patient risk precision generate basis recode entering components definitive full limited vehicles reached efficacy immune disorders shown portable vectors otherwise scope disease hurdles

Project "UPGRADE" data sheet

The following table provides information about the project.

Coordinator	FONDAZIONE TELETHON Organization address address: VIA VARESE 16/B city: ROMA postcode: 185 website: www.telethon.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	14˙996˙955 €
EC max contribution	14˙995˙830 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2023-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FONDAZIONE TELETHON FONDAZIONE TELETHON Organization address address: VIA VARESE 16/B city: ROMA postcode: 185 website: www.telethon.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	coordinator	5˙027˙968.00
2	UNIVERSIDAD POMPEU FABRA UNIVERSIDAD POMPEU FABRA Organization address address: PLACA DE LA MERCE, 10-12 city: BARCELONA postcode: 8002 website: www.upf.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	2˙767˙377.00
3	UNIVERSITA DEGLI STUDI DI TRENTO UNIVERSITA DEGLI STUDI DI TRENTO Organization address address: VIA CALEPINA 14 city: TRENTO postcode: 38122 website: www.unitn.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (TRENTO)	participant	1˙333˙798.00
4	VRIJE UNIVERSITEIT BRUSSEL VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 website: www.vub.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSEL)	participant	1˙328˙412.00
5	THE GENERAL HOSPITAL CORPORATION THE GENERAL HOSPITAL CORPORATION Organization address address: FRUIT STREET 55 city: BOSTON MA postcode: 2114 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (BOSTON MA)	participant	1˙217˙710.00
6	UNIVERSITE DE NANTES UNIVERSITE DE NANTES Organization address address: QUAI DE TOURVILLE 1 city: NANTES CEDEX 1 postcode: 44035 website: www.univ-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES CEDEX 1)	participant	1˙107˙500.00
7	TECHNISCHE UNIVERSITAET DRESDEN TECHNISCHE UNIVERSITAET DRESDEN Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 website: http://www.tu-dresden.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	1˙107˙000.00
8	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	1˙106˙062.00

Map

Project objective

Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene therapy products have reached the market and many more are entering clinical testing for selected indications. Moreover, emerging technologies for targeted gene editing are complementing the scope of conventional gene transfer, opening the way to precise gene correction and making possible to silence, activate or recode any sequence of interest in the genome. However, in order to realize the full potential of these strategies and broaden application of gene therapy, the field has to solve several major hurdles, including: risk of insertional mutagenesis by gene transfer vectors, limited efficiency and durability of some gene correction strategies, off target effects of editing tools, poor tissue targeting and immune response to editing components and delivery vehicles. UPGRADE will offer radical new solutions to overcome these hurdles. We will exploit and further develop disruptive new technologies for precision gene and epigenome editing and for site-specific transgene insertion, and stringently characterize their specificity and cellular responses. We will combine these improved technologies with advanced viral and non-viral vectors enabling cell/tissue targeting and immune evasion, to generate prototypes of advanced medicinal products (AMP). The safety and efficacy profile of each AMP will be stringently validated in tissues (hematopoiesis, heart and skeletal muscle, liver, retina) and disease models (muscle wasting, storage and blood disorders, hypercholesterolemia) paradigmatic for unmet medical need and potential long-term cure, if the limitations of current gene therapy strategies are overcome. These AMPs represent versatile products portable to the treatment of several other diseases because of related pathogenesis or correction strategies, thus providing the basis for tackling diseases affecting large patient groups.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UPGRADE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UPGRADE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More